TVRDTvardi Therapeutics, IncorporatedSigning up patients
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 193 (planned)
- Started
- Mar 23, 2023
- Main results expected
- May 25, 2027
- Fully finished
- Jul 20, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Adverse Events (AE)
Measured over: Up to approximately 20 months
Incidence of Serious Adverse Events (SAE)
Measured over: Up to approximately 18 months
Phase 2: Overall Response Rate (ORR) to TTI-101
Measured over: Up to approximately 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05440708 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC